Protalix Biotherapeutics (PLX)
XASE:PLX
Want to see PLX full AI Analyst Report?
PLX Stock Chart & Stats
$2.32
-$0.05(-2.01%)
At close: 4:00 PM EST
$2.32
-$0.05(-2.01%)
Day’s Range― - ―
52-Week Range$1.32 - $3.19
Previous CloseN/A
Volume368.29K
Average Volume (3M)783.40K
Market Cap
$169.20M
Enterprise Value$135.97M
Total Cash (Recent Filing)$51.79M
Total Debt (Recent Filing)$8.48M
Price to Earnings (P/E)2.4
Beta0.66
Next Earnings
Aug 17, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.19
Shares Outstanding80,571,640
10 Day Avg. Volume950,969
30 Day Avg. Volume783,404
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.93
Price to Sales (P/S)2.68
P/FCF Ratio-10.37
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue1.78
Enterprise Value/Gross Profit2.54
Enterprise Value/Ebitda6.38
Forecast
1Y Price Target
$12.00Price Target Upside417.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.22
Revenue Forecast (FY)$79.05M
Bulls Say, Bears Say
Bulls Say
Dosing Convenience And AdherenceAn every-four-weeks dosing schedule improves patient convenience and adherence, increasing the likelihood of capturing market share from competing enzyme replacement therapies.
Partnership Milestone And Cash OutlookEligibility to receive a milestone payment from a commercial partner upon approval of the new dosing regimen strengthens near-term cash prospects and supports commercial execution plans.
Regulatory ApprovalEuropean regulator approval of an every-four-weeks dosing option for Elfabrio expands the product label and validates a less frequent regimen for adults stable on enzyme replacement therapy.
Bears Say
Competitive LandscapeEstablished competing enzyme therapies in the European market may limit the speed and extent of Elfabrio adoption, constraining potential market share gains.
Revenue PerformanceReported product revenue missed analyst expectations, creating headwinds for near-term financial performance and investor confidence.
Protalix News
PLX FAQ
What was Protalix Biotherapeutics’s price range in the past 12 months?
Protalix Biotherapeutics lowest stock price was $1.32 and its highest was $3.19 in the past 12 months.
What is Protalix Biotherapeutics’s market cap?
Protalix Biotherapeutics’s market cap is $169.20M.
When is Protalix Biotherapeutics’s upcoming earnings report date?
Protalix Biotherapeutics’s upcoming earnings report date is Aug 17, 2026 which is in 82 days.
How were Protalix Biotherapeutics’s earnings last quarter?
Protalix Biotherapeutics released its earnings results on May 13, 2026. The company reported $0.22 earnings per share for the quarter, beating the consensus estimate of -$0.01 by $0.23.
Is Protalix Biotherapeutics overvalued?
According to Wall Street analysts Protalix Biotherapeutics’s price is currently Undervalued.
Does Protalix Biotherapeutics pay dividends?
Protalix Biotherapeutics does not currently pay dividends.
What is Protalix Biotherapeutics’s EPS estimate?
Protalix Biotherapeutics’s EPS estimate is -0.01.
How many shares outstanding does Protalix Biotherapeutics have?
Protalix Biotherapeutics has 80,571,640 shares outstanding.
What happened to Protalix Biotherapeutics’s price movement after its last earnings report?
Protalix Biotherapeutics reported an EPS of $0.22 in its last earnings report, beating expectations of -$0.01. Following the earnings report the stock price went up 1.047%.
Which hedge fund is a major shareholder of Protalix Biotherapeutics?
Currently, no hedge funds are holding shares in PLX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Protalix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (417.24% Upside)
$12.00 (417.24% Upside)
Blogger Sentiment
Neutral
PLX Sentiment 50%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.6%
Last 30 Days ▼ 4.3%
Last 30 Days ▼ 4.3%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
27.27%
12-Months-Change
Fundamentals
Return on Equity
28.10%
Trailing 12-Months
Asset Growth
38.49%
Trailing 12-Months
Company Description
Protalix Biotherapeutics
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.
PLX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive financial and operational picture driven by a $25 million milestone that produced Q1 profitability and strengthened the balance sheet to $51 million in cash. Management reaffirmed 2026 guidance and highlighted commercial and regulatory progress for Elfabrio and continued advancement of the PRX-115 program. Offsetting risks include a notable decline in product sales quarter-over-quarter (-26% in selling goods), increased R&D spend (+54%), and timing/visibility uncertainties tied to Chiesi reimbursement rollouts and trial enrollment pace. Overall, the positives (milestone, cash position, profitability, reaffirmed guidance, and clinical progress) materially outweigh the near-term revenue timing and expense increases.View all PLX earnings summariesPLX Stock 12 Month Forecast
Average Price Target
$12.00
▲(417.24% Upside)
Technical Analysis
Coherus Biosciences
―
SELLAS Life Sciences Group
―
Protara Therapeutics
―
Forte Biosciences
―
Innate Pharma
―
Ownership Overview
3.87% Insiders
2.66% Mutual Funds
6.20% Other Institutional Investors
83.01% Public Companies and
Individual Investors